Preterm Premature Rupture of Membrane Clinical Trial
Official title:
The Value of Amniopatch in Pregnancies Associated With Spontaneous Preterm Premature Rupture of Fetal Membranes:A Randomized Controlled Trial
A randomized controlled trial that involved 100 women diagnosed with PPROM between 24 and 34 weeks of gestational age. Participants were randomized equally into 2 groups. Group I in which amniopatch was done (an amnioinfusion of platelet concentrate followed by fresh frozen plasma in addition to the routine management used in the control group. Group II were treated with routine management including antibiotics and corticosteroids
All patients were started on a regimen of hospital bed rest and received antibiotic
prophylaxis consisting of ampicillin 2g IV every 6hours for 48 hours, followed by
erythromycin 250mg every 6hours for 5days . Antenatal corticosteroids were given in the form
of dexamethasone 8mg intramuscular every 12hours for 48 hours i.e. in four divided doses.
Fifty to two hundred ml of normal saline was infused to create an adequate pocket in which
the infusion needle can be stabilized. After injection of normal saline, alternate infusions
of 20 mL of platelets, normal saline (which does not contain Calcium, needed for the clotting
process), and 20 mL of (FFP). The infused substances were warmed to a temperature of 37°c.
Avoiding contact between the blood products prevents clotting in the lines.
During infusion, the fetal heart rate as well as the accumulation of amniotic fluid was
monitored by ultrasound. Usually a total of around 60-80 mL of platelets, 100-150 mL of FFP
and 100-150 mL of amnioinfusion fluid was used throughout the procedure
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04963465 -
The Accuracy of Amniotic Fluid Ferning in the Second Trimester in the Diagnosis of Preterm Prelabor Rupture of Membranes
|
||
| Recruiting |
NCT03992534 -
The FLIP-1 Study: Vaginal Lactobacillus Supplementation in Women at High Risk of Preterm Birth
|
Phase 1 | |
| Completed |
NCT04294069 -
Azithromycin Dose and PPROM Treatment: a Pilot Randomized Controlled Trial
|
Phase 4 | |
| Recruiting |
NCT03976063 -
Tocolysis in the Management of Preterm Premature Rupture of Membranes Before 34 Weeks of Gestation
|
Phase 3 | |
| Completed |
NCT01503606 -
Duration of Antibiotics Treatment With Cefazolin and Clarithromycin in Women With Preterm Premature Rupture of Membrane
|
Phase 3 | |
| Recruiting |
NCT04590677 -
Prediction of the Onset of Term and Preterm Labour
|
||
| Recruiting |
NCT04110704 -
Cerclage After Full Dilatation Caesarean Section
|
N/A | |
| Not yet recruiting |
NCT05328817 -
Azithromycin Versus Erythromycin For Preterm Prelabor Rupture of Membranes
|
N/A | |
| Recruiting |
NCT05353153 -
The Psychological Experience of Pathological Pregnancy. Study of the Case of Premature Rupture of Membranes and Evaluation of the Impact of Hypnosis Support
|
N/A | |
| Completed |
NCT03814278 -
Bed Rest After Preterm Premature Rupture of the Membranes
|
N/A | |
| Completed |
NCT04807543 -
Effect of Progesterone on Latent Phase Prolongation in Patients With Preterm Premature Rupture of Membranes
|
Phase 2 | |
| Recruiting |
NCT06443788 -
Trans-perineal Ultrasound in Assessment of PPROMs
|
N/A | |
| Not yet recruiting |
NCT05207800 -
Predictive Value of Maternal Serum Pentraxin 3 (PTX 3) and Heparin-binding Protein (HBP) for Chorioamnionitis in Preterm Premature Rupture of Membranes
|
||
| Recruiting |
NCT04705935 -
Amniochorionic Membrane Cells in the Maternal Blood as a Biomarker for Preterm Birth
|
||
| Not yet recruiting |
NCT06396078 -
Improvement of PPROM Management With Prophylactic Antimicrobial Therapy (iPROMPT)
|
Phase 4 | |
| Active, not recruiting |
NCT06074601 -
MIRACLE of LIFE Study
|
||
| Recruiting |
NCT04516226 -
Vaginal Cleansing With Chlorhexidine Gluconate in Women With Preterm Pre-labor Rupture of Membranes
|
N/A | |
| Recruiting |
NCT03306719 -
mtDNA as Novel Biomarker for Intra-amniotic Infection
|
N/A | |
| Not yet recruiting |
NCT06377397 -
Selective Antibiotics When Symptoms Develop Versus Universal Antibiotics for Preterm Neonates
|
Phase 3 | |
| Completed |
NCT04413019 -
Domiciliary Versus Hospital Management of PPROM
|